Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex-Reference-Cited by-同舟云学术

Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex

Published:2015-02-20 Issue:5 Volume:43 Page:2575-2589
ISSN:1362-4962
Container-title:Nucleic Acids Research
language:en
Short-container-title:

Author:

Ekumi Kingsley M.,Paculova Hana,Lenasi Tina,Pospichalova Vendula,Bösken Christian A.,Rybarikova Jana,Bryja Vitezslav,Geyer Matthias,Blazek Dalibor,Barboric Matjaz

Publisher

Oxford University Press (OUP)

Subject

Genetics

Link

http://academic.oup.com/nar/article-pdf/43/5/2575/16864794/gkv101.pdf

Reference55 articles.

1. Defining mechanisms that regulate RNA polymerase II transcription in vivo;Fuda;Nature,2009

2. The RNA polymerase II carboxy-terminal domain (CTD) code;Eick;Chem. Rev.,2013

3. RNA polymerase II elongation control;Zhou;Annu. Rev. Biochem.,2012

4. P-TEFb stimulates transcription elongation and pre-mRNA splicing through multilateral mechanisms;Lenasi;RNA Biol.,2010

5. CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1;Bartkowiak;Genes Dev.,2010

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of specific CDKs in regulating DNA damage repair responses and replication stress;Current Opinion in Pharmacology;2024-12

2. Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer;Molecular Cytogenetics;2024-05-04

3. CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer;Cancer Letters;2024-05

4. CDK12Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality;2024-03-21

5. Identification of a novel potent CDK inhibitor degrading cyclinK with a superb activity to reverse trastuzumab-resistance in HER2-positive breast cancer in vivo;European Journal of Medicinal Chemistry;2024-01